A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Summary

A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.

Timeline

Start

2018-02-01

Primary completion

2020-11-05

Completion

2020-11-05

Outcome

Outcome not reported

Stopped (Business): “The Relamorelin program is being terminated solely based on a business decision.”

Drugs

Indications